Videos

Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on the rollout of phase 1b and c of COVID-19 vaccinations at Walgreens pharmacies.

Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on whether any unforeseen problems have arisen during the first wave of COVID-19 vaccinations at long-term care facilities.

Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on the first wave of COVID-19 vaccine administration at long-term care facilities across the country.

Pharmacy Times® interviewed William von Oehsen, JD, principal at Powers Pyles Sutter & Verville, on a letter that was signed by President-elect Biden’s pick for HHS secretary to the outgoing HHS secretary on the enforcement of 340B drug pricing laws.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.

In a recent interview with Pharmacy Times, Barbara Giacomelli, BS Pharm, PharmD, discussed the trends she hopes to see in the pharmacy field in 2021 and where she sees the landscape changing.

Patrick Campbell, PharmD, PhD, the senior director of research at the Pharmacy Quality Alliance, discusses why sending a short video to a patient’s phone can improve primary medication adherence and why it’s more effective than text messages.

Pharmacy Times® interviewed William von Oehsen, JD, principal at Powers Pyles Sutter & Verville, on how pharmacies and their patients are affected by issues regarding the regulation of the sale of 340B discounted drugs.

Having a shared cultural understanding allows the pharmacy to make medical and educational interventions relevant to the patient and allows patients to actively participate in their care.

Pharmacy Times® interviewed William von Oehsen, JD, principal at Powers Pyles Sutter & Verville, on a lawsuit filed against the HHS and HRSA regarding the sale of 340B discounted drugs.